Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on August 6, 2020. The report addresses regulatory notifications received from the Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards. The Company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
Based on the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, the following financial metric is disclosed in this filing:
- Stockholders' Equity: $7,178,000 (Below the $10,000,000 minimum required for Nasdaq Global Market listing).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the equity figure cited for listing compliance purposes.
Material Changes and Listing Deficiencies
The Company received two written notifications from Nasdaq on August 6, 2020, citing non-compliance with listing rules:
- Minimum Stockholders' Equity Deficiency: The Company failed to meet Nasdaq Listing Rule 5450(b)(1)(A) due to stockholders' equity of $7,178,000, which is below the $10,000,000 threshold.
- Minimum Bid Price Deficiency: The Company failed to meet Nasdaq Listing Rule 5450(a)(1) as the closing bid price for its common stock remained below $1.00 for 30 consecutive business days.
Outlook, Management Commentary, and Risks
Compliance Timelines and Actions:
- Equity Deficiency: The Company has 45 days from the notice date to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days to cure the deficiency. Failure to submit an acceptable plan or cure the deficiency could lead to delisting.
- Bid Price Deficiency: The Company has 180 calendar days (until February 2, 2021) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if specific conditions are met.
Management Commentary: The Company intends to take all reasonable measures to regain compliance and remain listed on Nasdaq. It may also apply to transfer from the Nasdaq Global Market to the Nasdaq Capital Market if it satisfies those listing requirements.
Risks and Contingencies: There is no assurance that the Company will successfully appeal any adverse determinations, regain compliance with equity or bid price requirements, or avoid delisting. If delisted, the Company's shares may be subject to trading on the OTC market or other venues.
Investor Verification Checklist
- Verify the Company's current stockholders' equity and any capital raise activities intended to meet the $10 million threshold.
- Monitor the daily closing bid price of OBLN stock to track progress toward the $1.00 minimum requirement.
- Review any subsequent filings (e.g., 8-K or press releases) regarding the submission and acceptance of the compliance plan for the equity deficiency.
- Check for announcements regarding a potential transfer to the Nasdaq Capital Market.
- Confirm the status of the Company's appeal rights and deadlines for the February 2, 2021 bid price compliance deadline.